Familial adenomatous polyposis treatment market is anticipated to grow at a significant CAGR during the forecast period. Familial adenomatous polyposis (FAP) is an inherited disorder. It is characterized by the large intestine (colon) and rectum cancer. Additionally, the classic type of familial adenomatous polyposis in people begins to occur as early as in their teenage years causing them to develop multiple noncancerous in the colon. The major factor accelerating the growth of the market is the increasing prevalence of familial adenomatous polyposis across the globe.
According to the National Organization for Rare Disorders (NORD), FAP affects males and females equally and occurs in approximately one in 5,000 to 10,000 individuals in the US. Additionally, it accounts for about 0.5% of all cases of colorectal cancer. Furthermore, it is estimated that it affects almost 50,000 American families. Moreover, as per the American Society of Clinical Oncology (ASCO), it is estimated that most people with FAP will have multiple colon polyps by age 35 and approximately 30% of people with FAP do not have any family history of the condition. Further, it is estimated that people affected with FAP have a 100% risk of colorectal cancer if polyps are not removed. Hence, the rising prevalence of the disease is driving the demand for familial adenomatous polyposis treatment.
To Request a Sample of our Report on Familial Adenomatous Polyposis Treatment Market: https://www.omrglobal.com/request-sample/familial-adenomatous-polyposis-treatment-market
Some major players operating in the market include Cancer Prevention Pharmaceuticals Inc, Marina Biotech, Inc, and Thetis Pharmaceuticals LLC, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2020, Cancer Prevention Pharmaceuticals, Inc. announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA). It was aimed to receive accelerated approval for CPP-1X/sul for the treatment of adults with familial adenomatous polyposis (FAP).
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Cancer Prevention Pharmaceuticals Inc, Marina Biotech Inc, and Thetis Pharmaceuticals LLC, among others.
Familial Adenomatous Polyposis Treatment Market Report by Segment
By Type
- Icosapent
- Eflornithine Hydrochloride
- Aspirin
- CEQ-508
- Others
By Application
- Hospital
- Clinics
- Others
A full Report of Familial Adenomatous Polyposis Treatment Market is Available @ https://www.omrglobal.com/industry-reports/familial-adenomatous-polyposis-treatment-market
Familial Adenomatous Polyposis Treatment Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
